Total
0
Shares
PainChek (ASX:PCK) - CEO, Philip Daffas - The Market Herald
CEO, Philip Daffas
Source: PainChek
  • PainChek (PCK) has extended its partnership contract with AlayaCare -opening the opportunity for PainChek to enter the Canadian home care market
  • PainChek will integrate its smartphone-based pain assessment and monitoring tool with AlayaCare's home care software platform
  • AlayaCare is a Montreal-based home healthcare company that provides software to 500 home and community care organisations
  • While the companies have an existing agreement in Australia, this extended partnership opens doors to new opportunities in Canada
  • The Canadian home care market is worth around $5 billion and presents a sizeable opportunity for PainChek
  • However, PainChek must first receive regulatory approval in Canada before it can actively sell its technology
  • Company shares ended the day trading a slight 2.22 per cent higher for 9.2 cents

PainChek (PCK) has extended its partnership agreement with AlayaCare which opens the opportunity for PainChek to enter the Canadian home care market.

AlayaCare is a Montreal-based home healthcare company that provides software to 500 home and community care organisations

Its end-to-end solution includes clinical documents, back office functionality, client and family portals, remote patient monitoring and mobile care worker functions.

Under the agreement, PainChek's unique pain assessment tool will be integrated with AlayaCare's home care software platform and made available to clients in Canada. The extended agreement will complement the parties' existing relationship in Australia.

PainChek's namesake technology is a world-first, smartphone-based pain assessment and monitoring application which is generally catered towards people with Alzheimer's or dementia.

The smartphone camera records a video of the person's face then analyses the images using facial recognition analytics. It automatically recognises and records facial muscle movements that indicate levels of pain.

PainChek then calculates an overall pain score and stores the result. This allows the caregiver to monitor the effect of medication and treatment over time.

"We’ve had an excellent working relationship with AlayaCare in the Australian market for both the residential aged care and home care sectors, and we are eager to take this to the Canadian home care market," PainChek CEO Philip Daffas said.

The Canadian home health and support services market is worth $5 billion which provides PainChek with a significant opportunity. It's expected that one million Canadians are receiving care in a home or community-based setting.

"PainChek is another high-quality, better outcomes feature for our cloud-based home health software solution that spans clinical, scheduling, billing, advanced reporting and more," AlayaCare Vice President of Strategy and Corporate Development Neil Grunberg said.

AlayaCare will provide lead generation and marketing support to PainChek while PainChek will be responsible for direct sales, training and technical support to the Canadian client base.

Active selling to clients will begin once PainChek receives regulatory clearance from Health Canada. This is expected before the end of the year.

Company shares ended the day trading a slight 2.22 per cent higher for 9.2 cents.


Subscribe


PCK by the numbers
More From The Market Herald
Factor Therapeutics (ASX:FTT) pulls out of LONGMILE transaction

" Factor Therapeutics (ASX:FTT) pulls out of LONGMILE transaction

Biotechnology company Factor Therapeutics (FTT) has cancelled its proposed transaction with LONGMILE Veterinary PET Imaging.
Prescient Therapeutics (ASX:PTX) - CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) to begin three next-gen CAR T programs

Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform, OmniCAR.
Cyclopharm (ASX:CYC) - Managing Director and CEO, James McBrayer (right) - The Market Herald

" Cyclopharm (ASX:CYC) progresses U.S. FDA approval for Technegas

Cyclopharm (CYC) has announced its Technegas product is on track to receive United States Food and Drug Administration (FDA) approval in the first
Orthocell (ASX:OCC) - Managing Director, Paul Anderson - The Market Herald

" U.S. FDA clears Orthocell’s (ASX:OCC) CelGro product

Orthocell (OCC) has received Food and Drug Administration (FDA) 501K approval to supply and market its medical collagen product CelGro in the U.S.